Literature DB >> 30093564

Digital PCR-Based T-cell Quantification-Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma.

Mark J de Lange1, Rogier J Nell1, Rajshri N Lalai1, Mieke Versluis1, Ekaterina S Jordanova2,3, Gre P M Luyten1, Martine J Jager1, Sjoerd H van der Burg4, Willem H Zoutman5, Thorbald van Hall4, Pieter A van der Velden6.   

Abstract

Uveal melanoma progression can be predicted by gene expression profiles enabling a clear subdivision between tumors with a good (class I) and a poor (class II) prognosis. Poor prognosis uveal melanoma can be subdivided by expression of immune-related genes; however, it is unclear whether this subclassification is justified; therefore, T cells in uveal melanoma specimens were quantified using a digital PCR approach. Absolute T-cell quantification revealed that T-cell influx is present in all uveal melanomas associated with a poor prognosis. However, this infiltrate is only accompanied by differential immune-related gene expression profiles in uveal melanoma with the highest T-cell infiltrate. Molecular deconvolution of the immune profile revealed that a large proportion of the T-cell-related gene expression signature does not originate from lymphocytes but is derived from other immune cells, especially macrophages. Expression of the lymphocyte-homing chemokine CXCL10 by activated macrophages correlated with T-cell infiltration and thereby explains the correlation of T-cell numbers and macrophages. This was validated by in situ analysis of CXCL10 in uveal melanoma tissue with high T-cell counts. Surprisingly, CXCL10 or any of the other genes in the activated macrophage-cluster was correlated with reduced survival due to uveal melanoma metastasis. This effect was independent of the T-cell infiltrate, which reveals a role for activated macrophages in metastasis formation independent of their role in tumor inflammation. IMPLICATIONS: The current report uses an innovative digital PCR method to study the immune environment and demonstrates that absolute T-cell quantification and expression profiles can dissect disparate immune components. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30093564     DOI: 10.1158/1541-7786.MCR-18-0114

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  14 in total

1.  Identification of canonical NFκB (C-NFκB) pathway in uveal melanoma and their relation with patient outcome.

Authors:  Mithalesh Kumar Singh; Lata Singh; Neelam Pushker; Neeru Saini; Rachna Meel; Kunzang Chosdol; Sameer Bakhshi; Seema Sen; Pradeep Venkatesh; Bhavna Chawla; Jasbir Kaur; Seema Kashyap
Journal:  Clin Exp Metastasis       Date:  2019-05-08       Impact factor: 5.150

2.  Spatial Mapping of Myeloid Cells and Macrophages by Multiplexed Tissue Staining.

Authors:  Joshua Saylor; Zhaoxuan Ma; Helen S Goodridge; Fangjin Huang; Anne E Cress; Stephen J Pandol; Stephen L Shiao; Adriana C Vidal; Lily Wu; Nicholas G Nickols; Arkadiusz Gertych; Beatrice S Knudsen
Journal:  Front Immunol       Date:  2018-12-14       Impact factor: 7.561

Review 3.  HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target.

Authors:  Zahra Souri; Annemijn P A Wierenga; Arend Mulder; Aart G Jochemsen; Martine J Jager
Journal:  Cancers (Basel)       Date:  2019-08-07       Impact factor: 6.639

4.  Clinical protein science in translational medicine targeting malignant melanoma.

Authors:  Jeovanis Gil; Lazaro Hiram Betancourt; Indira Pla; Aniel Sanchez; Roger Appelqvist; Tasso Miliotis; Magdalena Kuras; Henriette Oskolas; Yonghyo Kim; Zsolt Horvath; Jonatan Eriksson; Ethan Berge; Elisabeth Burestedt; Göran Jönsson; Bo Baldetorp; Christian Ingvar; Håkan Olsson; Lotta Lundgren; Peter Horvatovich; Jimmy Rodriguez Murillo; Yutaka Sugihara; Charlotte Welinder; Elisabet Wieslander; Boram Lee; Henrik Lindberg; Krzysztof Pawłowski; Ho Jeong Kwon; Viktoria Doma; Jozsef Timar; Sarolta Karpati; A Marcell Szasz; István Balázs Németh; Toshihide Nishimura; Garry Corthals; Melinda Rezeli; Beatrice Knudsen; Johan Malm; György Marko-Varga
Journal:  Cell Biol Toxicol       Date:  2019-03-21       Impact factor: 6.691

5.  Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study.

Authors:  Markus V Heppt; Teresa Amaral; Katharina C Kähler; Lucie Heinzerling; Jessica C Hassel; Markus Meissner; Nicole Kreuzberg; Carmen Loquai; Lydia Reinhardt; Jochen Utikal; Evelyn Dabrowski; Anja Gesierich; Claudia Pföhler; Patrick Terheyden; Kai-Martin Thoms; Lisa Zimmer; Thomas K Eigentler; Michael C Kirchberger; Henner M Stege; Friedegund Meier; Max Schlaak; Carola Berking
Journal:  J Immunother Cancer       Date:  2019-11-13       Impact factor: 13.751

6.  Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma.

Authors:  Rogier J Nell; Nino V Menger; Mieke Versluis; Gregorius P M Luyten; Robert M Verdijk; Michele C Madigan; Martine J Jager; Pieter A van der Velden
Journal:  BMC Cancer       Date:  2021-02-15       Impact factor: 4.430

Review 7.  Scientific and clinical implications of genetic and cellular heterogeneity in uveal melanoma.

Authors:  Mark J de Lange; Rogier J Nell; Pieter A van der Velden
Journal:  Mol Biomed       Date:  2021-08-20

Review 8.  CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.

Authors:  Nathan Karin
Journal:  Front Immunol       Date:  2020-05-29       Impact factor: 7.561

9.  Immunological analyses reveal an immune subtype of uveal melanoma with a poor prognosis.

Authors:  Hui Pan; Linna Lu; Junqi Cui; Yuan Yang; Zhaoyang Wang; Xianqun Fan
Journal:  Aging (Albany NY)       Date:  2020-01-18       Impact factor: 5.682

10.  Development and validation of an immune and stromal prognostic signature in uveal melanoma to guide clinical therapy.

Authors:  Qianwen Gong; Qi Wan; Anqi Li; Yubin Yu; Xiangyu Ding; Lei Lin; Xiaoliang Qi; Liang Hu
Journal:  Aging (Albany NY)       Date:  2020-10-26       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.